TIL Healthcare Pharma Plant Blast in Andhra Pradesh’s Sri City Leaves Workers Dead and Injured
A boiler explosion at the TIL Healthcare plant in Sri City, Andhra Pradesh killed five workers and injured over 10 on 3 October; cause is under probe.
TIL Healthcare Pharma Plant Blast in Andhra Pradesh’s Sri City Leaves Workers Dead and Injured
A boiler explosion at the TIL Healthcare plant in Sri City, Andhra Pradesh killed five workers and injured over 10 on 3 October; cause is under probe.
Roche Launches Newborn Screening Test for SMA, SCID, SCD
Roche launches a CE-marked newborn screening test that detects SMA, SCID and sickle cell disease in one assay on LightCycler systems; not sold in the US.
Rakovina and Celvion Partner on AI-Driven Cancer Therapy
Rakovina Celvion partnership uses the EMphora AI platform and real-world clinical data to guide ATR inhibitor development; no financial terms disclosed.
Ensera Launches Alliance Network for Combination Products
Ensera alliance network links SHL Medical, Stevanato, Ypsomed, Argonaut and American Injectables to speed drug-device combination product supply.
Artificial Organs Market to Top $63 Billion by 2035
Artificial organs market size was $28.71 billion in 2025 and is projected to top $63.31 billion by 2035 at an 8.2% CAGR, led by North America.
AI in Neurosurgery Market to Reach $11.3 Billion by 2035
AI in neurosurgery market size was $850 million in 2025 and is forecast to hit $11.3 billion by 2035 at a 29.5% CAGR, led by North America and software.
AI in Healthcare Market to Reach $1.14 Trillion by 2035 at 39.1% CAGR
The AI in healthcare market was valued at $41.84 billion in 2025 and is projected to top $1.13 trillion by 2035, growing at a 39.1% CAGR led by North America.
Terumo Neuro Arsenal Medical Deal Adds Liquid Embolic
Terumo Neuro Arsenal Medical deal: Terumo Neuro agreed to buy Arsenal Medical and its NeoCast liquid embolic for chronic subdural hematoma.
Tulisokibart Hidradenitis Suppurativa Trial Meets Endpoint
Tulisokibart hidradenitis suppurativa results: Merck’s Phase 2b trial met its HiSCR50 primary endpoint at week 16, with 72% response on the high dose.
